Phase 1 N=26 Absolute BA and OZ439 PK Effect of Different OZ439 Dose Volumes and Cobicistat Co-administration Study
Malaria
Primary: OZ439 Fpo — 35 Absolute bioavailability in %
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=330 Comparison Between Quadruple Regimens for Helicobacter Pylori Infection in Egypt
Helicobacter Pylori Infection
Primary: Percentage of Helicobacter Pylori Infection Cure — 102; 101; 91 Participants
N/A N=746 Cesarean Trial of Staples vs. Sutures
Cesarean Section · Wound Complications · Patient Satisfaction
Primary: Number of Participants With Wound Complications — 18; 40; 9; 14 Participants
Phase 1 N=20 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-925 Study in Sleep-Deprived Healthy Adults
Healthy Volunteers
Primary: Latency to Sleep Onset on Maintenance of Wakefulness Test (MWT) at 2 Hours Post-infusion Start — 15.68; 35.74; 40.02; 35.57 minute — p=<0.001
Phase 2 N=2 Adjuvant Proton Therapy or IMRT for the Treatment of Bladder Cancer
Urothelial Carcinoma of the Bladder
Primary: Number of Participants With Adverse Events — 2 Participants
N/A N=15 Effects of Carrageenan-Elimination Diet on Ulcerative Colitis Disease Activity
Ulcerative Colitis
Primary: Number of Relapses by Group — 0; 3 relapses — p=0.046
N/A N=16 Suitability of DCE-MRI for Detection of Vascular Changes After VBT
Carcinoma of the Cervix, Carcinoma or Carcinosarcoma of the Uterus
Primary: Number of Participants With Adverse Events — 10 Participants
N/A N=500 Rapid Identification and Phenotypic Susceptibility Testing for Gram-Negative Bacteremia
Gram-negative Bacteremia
Primary: Hours to First Antibiotic Modification — 24.7; 19.0 hours — p=0.013
Phase 3 N=372 Implementation Effectiveness and Safety of Tenofovir Gel Provision Through Family Planning Services
HIV
Primary: Mean Number of Returned Used Applicators Per Month (i.e in 30 Days) — 5.2; 5.7; 5.5; 5.8 Used gel applicators per month
Phase 2 N=159 Safety & Efficacy of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Recipients
Heart Failure · Cardiomyopathy · Ventricular Dysfunction
Primary: Number of Temporary Weans From LVAD Support Tolerated — 0.61; 0.58 number of weans
N/A N=324 Promoting Physical Growth and Positive Development in Severely Stunted Guatemalan Children
Malnutrition · Developmental Disabilities
Primary: Change in Height/Length for Age Z Score — -0.02; 0.05 Z scores
N/A N=99 Regular vs Intermittent Dose Ibuprofen for the Treatment of Ankle Sprains in Children
Ibuprofen · Ankle Injuries
Primary: Change in Visual Analog Scale (VAS) Pain on Weight Bearing From Baseline — 6.96; 6.70 mm
Phase 2 N=59 Initial Dosing of BI 655130 in Palmoplantar Pustulosis Patients
Psoriasis
Primary: Percentage of Participants With Palmoplantar (pp) Pustular Psoriasis Area and Severity Index 50 (PASI) (ppPASI50) at Week 16 — 31.6; 31.6; 23.8 Percentage of…
Phase 2 N=72 A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Participants With Refractory or Relapsed Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Primary: Overall Response Rate (ORR) as Assessed by the Investigator Using the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 Criteria — 78.6 percentage of…
Phase 4 N=154 Intravenous Lidocaine Randomized Comparative Effectiveness Trial
Abdominal Pain
Primary: Change in 0-10 Pain Scale Between Baseline and 90 Minutes — 5.0; 3.8 units on a scale